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Abstract
Decapping by Dcp2 is an essential step in 5′-3′ mRNA decay. In yeast, decapping requires an 
open-to-closed transition in Dcp2, though the link between closure and catalysis remains elusive. 
Here we show using NMR that cap binds conserved residues on both the catalytic and regulatory 
domains of Dcp2. Lesions in the cap-binding site on the regulatory domain reduce the catalytic 
step two orders of magnitude and block formation of the closed state whereas Dcp1 enhances the 
catalytic step by a factor of ten and promotes closure. We conclude that closure occurs during the 
rate-limiting catalytic step of decapping, juxtaposing the cap-binding region of each domain to 
form a composite active site. This work suggests a model for regulation of decapping, where 
coactivators trigger decapping by stabilizing a labile composite active site.
Degradation of messenger RNA plays a crucial role in animal development1, cell 
proliferation2,3, differentiation4, stress responses5, the adaptive immune system6, and 
transcript quality control7. Removal of the 5′-terminal cap structure by the mRNA 
decapping enzyme Dcp2 is a critical step in numerous 5′–3′ decay pathways including bulk 
5′–3′ decay8,9, AU-rich element mediated decay10,11, nonsense-mediated decay (NMD)7,12, 
miRNA induced decay13–15 and 3′ uridylation16–19. In these pathways, decapping is an 
irreversible step that exposes the 5′ monophosphate of the RNA body for recognition by 
conserved 5′–3′ exonucleases20. Decapping is thus a highly regulated, committed step that 
sentences an mRNA to destruction.
Regulation of decapping is achieved by a dense network of protein-protein interactions 
impinging on the decapping enzyme Dcp2 (refs. 7,14,21–25). Though activation of decapping 
could be accomplished by targeting the decapping complex to a substrate mRNA, recent 
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work revealed that a conformational change in yeast Dcp2 is used to achieve a switch like 
response in activity26,27. Crystallographic studies26,28 indicate the conserved N-terminal 
region of Dcp2 has a bi-lobed architecture containing a regulatory domain, which binds the 
essential activator Dcp1, and a catalytic domain of the Nudix hydrolase superfamily (Fig. 
1a)26,29,30. The co-crystal structure of the S. pombe Dcp1-Dcp2 complex (ref. 26) displayed 
two conformations of Dcp2: one extended and unliganded and the other compact and bound 
to ATP (Supplementary Fig. 1a). NMR and kinetic studies revealed an RNA binding 
channel that bisects the regulatory and catalytic domains, suggesting conformational 
transitions in Dcp2 control an aspect of substrate recognition and catalysis26,27.
Four observations suggest conversion between open and closed states is required for 
efficient decapping. First, the regulatory domain and Dcp1 together contribute a factor of 
1,000 to the catalytic step and ensure correct bond hydrolysis27,31 but are far removed from 
the active site in the open form of the Dcp1-Dcp2 complex (Supplementary Fig. 1a)26. 
Second, the regulatory domain and Dcp1 are essential fordecapping in budding yeast9,28. 
Third, introduction of prolines in the interdomain linker block closure as detected by small 
angle X-ray scattering (SAXS) and hinder decapping in vitro26. Finally, the proline 
mutations mimic the effect of a Dcp2 knockout on reporter mRNA half life in vivo and 
cause accumulation of Dcp2 in P-bodies26. Enlarged P-bodies are also a consequence of 
lesions in a variety of coactivators of decapping, implicating this conformational change in 
activation of decapping in vivo14,22,32–34. These findings support the notion that 
conformational changes in Dcp2 constitute a critical, regulated step governing mRNA 
decapping and transcript stability.
An unresolved question is how closure in Dcp2 is linked to efficient cap hydrolysis. Using 
the crystal structure of the fission yeast Dcp1-Dcp2complex as a guide(ref. 26), we show that 
mutation of conserved residues of the regulatory domain retards the catalytic step and blocks 
closure. Surprisingly, a surface of the regulatory domain specifically interacts with m7G 
whereas the catalytic domain binds multiple nucleotides using different surfaces. We show 
Dcp1 enhances the catalytic step by a factor of 10 in vitro likely by stabilizing the closed 
conformation26. We propose a composite active site model of decapping, where the 
regulatory domain makes specific interactions with the cap positioning it for 
pyrophosphatase chemistry catalyzed by the Nudix domain.
RESULTS
Mutations on the regulatory domain retard the catalytic step
To determine how closure contributes to catalysis we sought to disrupt the closed crystal 
form (2QKM.pdb, ref. 26) and test for kinetic defects. We selected sites along the 31–52 
helix of S. pombe Dcp2 involved in the closed-form interdomain interface, mutated them to 
alanine, and performed kinetic analyses (Fig. 1a,b)27,35. Due to their superior solubility we 
used decapping proteins from S. pombe and cite residue numbers accordingly. Candidate 
interactions that could stabilize the closed form include a salt bridge between Glu39 and 
Arg95, an apparent cation-pi interaction between Trp43 and Arg167, and a contact between 
Asp47 and the backbone of Tyr220 (Fig. 1b)26. We narrowed our focus to Trp43 and Asp47 
as a previous alanine scanning study indicated mutation of these conserved residues resulted 
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in the strongest decapping defects observed on a reporter mRNA in yeast28. Alanine 
substitution at positions 43 and 47 strongly attenuated decapping activity in our single-
turnover kinetic assay, consistent with previous in vitro endpoint assays (Fig. 1c)28. 
Mutation at Trp43 or Asp47 reduces the catalytic step (kmax)by a factor of 20 or 100 
respectively, whereas KM was nearly unchanged (Fig. 1d and Table 1). Given the location of 
Trp43 and Asp47 the attenuation of the catalytic step is likely by destabilizing the active 
species.
Mutations on the regulatory domain block closure
The kinetic analyses above cannot distinguish between defects in conformational changes or 
chemistry since both are proposed to occur in the catalytic step. As such, we turned to SAXS 
to directly test the effect of the mutants on conformational changes in Dcp2. It was 
previously established that a compaction of the Dcp1-Dcp2 complex occurs in the presence 
of ATP or substrate analogs26. We reproduced these data on a C-terminal deletion construct 
(1–243) that is more amenable to solution NMR spectroscopy but has the same activity in 
vitro (Fig. 2a and Supplementary Fig. 1b). The distance distribution function P(r) reveals a 
compaction in the presence of cap-analog m7GpppA that is small but reproducible (n=3) 
(Fig. 2b). In response to nucleotide addition the radius of gyration Rg shrinks from 31.4 ± 1 
Å to 28.1 ± 1 Å and the maximum interatomic distance Dmax is reduced from 135 ± 10 Å to 
105 ± 10 Å in the unbound and liganded experiments, respectively. The region of P(r) which 
changes upon ligand addition (60–100Å) is similar to the region which changes between the 
computed P(r) curves from the open and closed crystal forms (Supplementary Fig. 1c–e). 
Differences between the apo solution scattering and open crystal form (Supplementary Fig. 
1c), or the liganded solution scattering and closed crystal form (Supplementary Fig. 1d) 
likely result from averaging due to a heterogeneous population, potentially including a 
mixture of the open and closed crystal forms or alternative states.
In contrast to the compaction observed in wild-type Dcp1-Dcp2, SAXS analysis of the 
Dcp1-Dcp2 W43A mutation shows no change in Rg or the distance distribution function 
between 60 and 100 Å upon addition of cap analog (Fig. 2c). The D47A mutation did not 
have a visible effect on the SAXS distance distribution function (data not shown). We 
therefore conclude that mutation at Trp43 alters the conformational states accessible to Dcp2 
and that Asp47 may affect either or both the chemical and conformational steps.
Dcp1 enhances the catalytic step
Previous kinetic studies of S. cerevisiae proteins indicated that Dcp1 and the regulatory 
domain of Dcp2 contribute a factor of 1,000 to the catalytic step of decapping27. Unlike the 
decapping proteins from S. cerevisiae, Dcp1 and Dcp2 from S. pombe can be expressed in E. 
coli and purified separately28, allowing us to directly quantify the catalytic enhancement by 
Dcp1. Dcp1 stimulates the catalytic step (kmax) by 10 times with only a small change in KM 
(Fig. 1c,d and Table 1). Nucleotide-driven closure of S. pombe Dcp2 was only detected by 
SAXS in the presence of Dcp1, suggesting it may affect the conformational equilibrium that 
could manifest in this rate enhancement26. Therefore, the enhancement previously 
measured27 consists of a factor of 10 from Dcp1 and 100 from the regulatory domain.
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The ATP-bound and active forms may be distinct
The rationale for mutation at Trp43 is its apparent cation-pi interaction with Arg167 in the 
ATP-bound closed conformation (Fig. 1b)26. However, mutation of the non-conserved 
residue Arg167 to glutamine (Fig. 1c,d) or alanine has no effect on decapping in vitro26. 
Consistent with the kinetic data, R167Q transitions into a compact state upon addition of 
m7GpppA (Fig. 2d). Differences in the R167Q distance distribution functions (Fig. 2d) 
compared to wild-type (Fig. 2b) are largely due to a difference in unliganded R167Q versus 
unliganded wild-type Dcp2. Therefore, Trp43 retards the catalytic step by blocking closure 
independent of Arg167, and conversely Arg167 is not involved in stabilizing the active 
conformation of Dcp2. This suggests that the interdomain interface in the active form may 
be different than that observed in the ATP-bound crystal structure26.
The regulatory domain harbors a binding site for cap
Previously we determined that substrate RNA is bound by the catalytic domain of S. 
cerevisiae Dcp2and that N7-methyl cap is specifically recognized during the catalytic step 
(ref. 27). However, it was not possible to address the structural foundation of this effect due 
the limited solubility of budding yeast Dcp2 constructs27. Since closure is promoted by 
nucleotide, we reasoned that formation of a compact, active form was likely driven by direct 
contacts between the two domains and cap. Therefore, we employed a fragment-based 
strategy to test the ability of each domain of S. pombe Dcp2 to bind m7GDP product and a 
panel of nucleotides by NMR, starting with the regulatory domain (residues 1–94, Fig. 1a). 
Surprisingly we found that the regulatory domain has an evolutionarily conserved binding 
site for m7GDP (Fig. 3a,b). Strong chemical shift perturbations were detected at both the 
Trp43 and Asp47 positions and the surrounding 31–52 helix (Fig. 3c,d and Supplementary 
Fig. 2a). The HSQC titrations were fit well by a two-state binding model that is used 
throughout to calculate dissociation constants, consistent with the colinearity of the chemical 
shift perturbations (Fig. 3c,d and Supplementary Fig. 2b). Fitting of HSQC titrations for the 
Trp43 indole and Asp47 backbone amide yields a Kd for m7GDP of roughly 12 mM 
suggesting a concerted binding process (Supplementary Table 1). Direct binding of cap by 
the regulatory domain suggests how substrate binding may stimulate closure.
We next tested the specificity of this binding site by titrating different nucleotides against 
the domain and found that GDP binds weakly to the same site (Fig. 3e,f and Supplementary 
Fig. 2c) and neither ATP nor other nucleoside diphosphates bound to this site 
(Supplementary Fig. 2d and data not shown). Quantification of the data shows that the GDP 
Kd is weaker at ~40 mM (Supplementary Fig. 2e and Supplementary Table 1). Therefore 
this site is specific for the guanine base and has enhanced affinity for the N7-methylated 
form. Critically, mutation of Trp43 to alanine blocks m7GDP binding, directly implicating 
Trp43 in the binding process, and suggesting that mutation at Trp43 blocks closure by 
decoupling the regulatory domain from cap recognition (Supplementary Fig. 2f).
Since m7GDP is a product of the decapping reaction, it is possible that its binding to the 
regulatory domain is different than that of the substrate RNA cap. Therefore, we tested 
binding of the cap-analog m7GpppA and found that it binds to the same surface with nearly 
identical affinity as m7GDP (Supplementary Fig. 3 and Supplementary Table 1). In contrast, 
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ApppA does not bind the regulatory domain (Supplementary Fig. 4). These data indicate that 
the addition of adenine, which would correspond to the first transcribed nucleotide of the 
mRNA, does not affect the recognition of m7G by the regulatory domain.
The catalytic domain binds m7G and ATP at different sites
If there is a ligand-dependent coupling between the two domains then the catalytic domain 
should also bind nucleotide. To test this we again used HSQC titration to assess the 
nucleotide binding ability of the catalytic domain (residues 95–243 of S. pombe Dcp2, Fig. 
1a). Three regions were perturbed upon addition of nucleotide: the convex dorsal surface 
(residues 224–243), the ATP-binding pocket in the crystal structure of spDcp1-Dcp2 
(residues 116–122, 129, 220–222, ref. 26), and the catalytic helix (residues 136–148). There 
is a clear difference in the binding profile of m7GDP and ATP for these regions (shifts 
depicted on PDB 2QKM, Fig. 4 and Supplementary Fig. 5). The dorsal surface was 
perturbed upon addition of either ATP or m7GDP (Fig. 4d,f). This region is positively 
charged and was shown to bind the RNA body nonspecifically, consistent with its lack of 
specificity for nucleotide27. Similarly, the ATP-binding pocket of the protein is the 
canonical substrate binding region in Nudix hydrolases29 and binds both nucleotides tested. 
We directly tested the contribution of the gamma phosphate on ATP by titrating ADP 
against the catalytic domain and find results similar to ATP but with reduced affinity, 
consistent with the interaction being driven by electrostatics (Supplementary Fig. 6 and 
Supplementary Table 1). Importantly, there is excellent agreement between the ATP binding 
site in the closed crystal state26, the RNA binding channel determined in a previous study27, 
and the regions detected by NMR chemical shift perturbation in this work.
In contrast to the dorsal surface and the ATP binding pocket, the catalytic helix was 
selectively perturbed upon addition of m7GDP but not ADP or ATP (Fig. 4a,b,e,g and 
Supplementary Figure 6). Binding of m7GDP also caused perturbations around the 
catalytically essential residue Glu192, pointing at a potential interaction between Glu192 
and cap or remodeling of the 161–194 loop that is not detected by NMR in the presence of 
ATP or ADP (Figs. 1b,4a and Supplementary Figure 5a) The previously determined location 
of the 5′ phosphate of the RNA body places the cap close to the catalytic helix, which is 
consistent with the perturbations we see upon addition of m7GDP. Moreover, we previously 
demonstrated that residues in the catalytic helix are perturbed by non-hydrolyzable capped 
RNA but not 5′ hydroxyl RNA27. In conclusion, the catalytic helix has a specific binding 
site for cap while the dorsal surface binds the RNA body.
We selected two probes for quantification: the conserved Nudix motif residue Glu146 on the 
catalytic helix and Lys235 on the RNA-binding region. ATP binds to the RNA binding helix 
(Lys235) with a Kd of roughly 5 mM but not detectably to the catalytic helix 
(Supplementary Fig. 5d and Supplementary Table 1). In contrast, m7GDP binds to the 
catalytic helix (Glu146) with a dissociation constant of 12 mM but only weakly perturbs the 
RNA binding helix (Supplementary Fig. 5c and Supplementary Table 1). Surprisingly, the 
affinity of m7GDP to the catalytic helix and regulatory domain are nearly identical, hinting 
at a concerted binding process in the two-domain protein. These results suggest Dcp2 has a 
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composite active site that forms as a result of closure, with cap specific contacts formed by 
the regulatory and catalytic domains.
DISCUSSION
In this work we uncovered the role of conformational changes in the catalytic mechanism of 
Dcp2 and the driving force for conversion into the active form. Dcp1 and the regulatory 
domain contribute factors of 10 and 100 to the catalytic step, respectively, by modulating 
conformational states of Dcp2 (Fig. 1). The regulatory domain enhances the catalytic step by 
specifically binding to m7G on a conserved surface surrounding Trp43 and Asp47 (Figs. 1,3 
and Supplementary Fig 3). Lesions in the cap binding site block closure and retard the 
catalytic step by up to two orders of magnitude (Figs. 1 and 2), consistent with the severe 
decapping defect in vivo upon mutation of Trp43 or Asp4728. These findings indicate that 
conversion to the active form of Dcp2 is driven through specific cap recognition by the 
regulatory domain and suggest that the active form harbors a composite active site with both 
domains sandwiching the cap.
Nudix family members contain a conserved catalytic motif with additional insertions or 
domains conferring substrate specificity29,36. Dcp2 conforms to this paradigm, with the 
catalytic domain performing chemistry and the regulatory domain providing specificity by 
accelerating catalysis on N7-methyl capped substrates. Interestingly, the addition of m7GDP 
perturbs residues on the conserved, catalytic Nudix helix whereas ATP and ADP do not 
(Figs. 4 and 5a). The regulatory domain may contribute to catalysis by positioning substrate 
as it is required to hydrolyze the correct phosphate bond31. High-resolution structural studies 
of Dcp2 in complex with substrate will be required to confirm this prediction.
The cap-bound conformation is different than the ATP-bound closed form for four reasons. 
First, the cap-binding residues Trp43 and Asp47 of the regulatory domain are buried in the 
closed structure and do not contact ATP (Fig. 1a,b)26. Second, the regulatory domain and 
catalytic helix both bind m7GDP by NMR but are separated by ~20 Å in the closed crystal 
structure (Fig. 5a)26. Third, Trp43 forms an apparent cation-pi interaction with Arg167 of 
the catalytic domain but mutating Arg167 to glutamine or alanine does not affect closure or 
decapping in vitro (Fig. 1b–d)26. Fourth, in the closed, ATP-bound form of Dcp1-Dcp2, 
non-conserved residues 244–266 of the catalytic domain fold into a helix that interacts with 
the regulatory domain, yet deletion of these residues has no effect on decapping or closure in 
vitro (Supplementary Fig. 1b)26,28. It is unclear whether the ATP-bound form represents an 
on-or off-pathway state, but it is accessible in solution since ATP causes closure26. Dcp2 
may assume different conformations from specific or non-specific interactions with 
substrate, as described for other nucleic acid binding proteins37,38. Given the composite 
active site suggested here and the previous crystal structure with open and closed 
conformations(ref. 26), we conclude that the native energy landscape of Dcp2 is rugged with 
multiple accessible states depending on the ligand.
Activation of decapping by closure was postulated to be a late step in 5′-3′ decay that is 
promoted by coactivators26,33. Dcp2 with proline hinge mutants blocking closure still 
localizes to P-bodies but decay of messages is blocked26. Large P-bodies containing Dcp2 
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and decay substrates are a hallmark of stalled decay complexes or overwhelmed decay 
machinery and are observed in coactivator mutants22,32,34. The proline hinge mutants also 
cause a dramatic defect in bulk mRNA decay both in vitro and in vivo26. The conformational 
change detailed here is likely part of this late, regulated step since mutation at Trp43 mimics 
the defect of the proline hinge mutants on closure in vitro and in vivo28. Therefore, closure 
and formation of the composite active site may couple decapping to stimulation by 
coactivators.
Our results are consistent with a model of decapping by Dcp2 where the catalytic step 
consists of at least two substeps beginning with isomerization to the active form (Fig. 5b) 
followed by the chemical step (Fig. 5c and Supplementary Note)39. In the open form the 
active site is incomplete, resulting in inefficient decapping (Fig. 5b and Supplementary 
Figure 1a). Cap recognition by both domains induces closure and forms a composite active 
site, allowing for efficient decapping (Fig. 5c). Previous experiments revealed that 5′-
monophosphate product RNA and non-hydrolyzable substrate RNA bind with the same 
affinity, suggesting cap recognition and closure occur after binding27. Dcp1 may accelerate 
the catalytic step by stabilizing the composite active site or enhancing the rate of closure. 
Like Dcp1, coactivators of decapping such as the Edc proteins in yeast40,41, the NMD 
factors Upf2 and Upf3 (ref. 33), the heptameric Lsm1–7 complex32, Pat132 and others may 
stimulate decapping by altering this conformational equilibrium. This is similar to regulation 
of DEAD-box helicases by cofactors that couple conformational changes to ATP hydrolysis 
using a bipartite active site42,43. The scavenger decapping enzyme DcpS also utilizes a 
composite active site to decap 3′-5′ exosomal decay products but is different in fold, 
chemistry, and regulation44,45. For Dcp2, coactivators play a critical role in regulation and 
the new understanding of the active form presented here motivates further mechanistic 
studies to determine how regulation is achieved in different 5′-3′ mRNA decay pathways.
METHODS
Protein purification, mutagenesis, and decapping complex formation
S. pombe Dcp2 (spDcp2) 1–243 and S. pombe Dcp1 1–127 were PCR amplified from S. 
pombe cDNA and cloned into p-His-GB1-parallel47. The catalytic domain(95–243) was 
PCR amplified from spDcp2 1–243 and cloned into p-His-GB1-parallel, while the 
regulatory domain (1–94) was PCR amplified from spDcp2 1–243 and cloned into a vector 
derived from pet28a consisting of a His-tag, Tobacco Etch Virus (TEV) protease site and a 
multiple cloning site (His–TEV–Dcp2–1–94). All proteins were expressed independently in 
E. coli. Cells were lysed by sonication, clarified by centrifugation at 16,000g then 
overexpressed proteins were purified using Ni-NTA affinity chromatography. Elutions were 
digested with TEV protease and then subjected to a second Ni-affinity column to remove the 
His-GB1 tag. The second Ni-purification was not used in purification of Dcp2 1–94 because 
the His tag is easily resolved by gel filtration. The Dcp1-Dcp2 complex was formed 
following TEV protease cleavage by incubation of 1.1:1 Dcp1:Dcp2 molar ratio for four 
hours in 4 °C prior to gel filtration. All mutants were made using whole plasmid PCR with 
mutagenic divergent primers; sequences of the Dcp2 ORF were confirmed by dideoxy 
sequencing.
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NMR Spectroscopy
Proteins were purified as above and subjected to gel filtration chromatography using a 
Superdex G75 column in 200 mM NaCl, 100 mM Na2SO4, 5 mM DTT, 21.1 mM 
NaH2PO4, and 28.8 mM Na2HPO4 pH 7.0 for storage and backbone resonance assignment. 
Prior to nucleotide titrations, proteins were exchanged into 150 mM NaCl, 2 mM MgCl2, 5 
mM DTT and 50 mM HEPES pH 7.0 using a desalting column (BioRad). Titrations on the 
regulatory domain were done at 100 μM protein in a volume of 500 μL by simultaneous 
addition of equimolar nucleotide and magnesium. Titrations on the catalytic domain were 
identical except done in the absence of magnesium. All titration experiments were 
conducted on a Bruker Avance 800 MHz spectrometer outfitted with a cryogenic probe. 
Titration data were only fitted if the change in chemical shift between apo and 30 mM 
nucleotide for a given residue was greater than the mean plus one standard deviation. 
Assignments were obtained from standard triple-resonance experiments48 (HNCA, 
HNCOCA, HNCO, HNCACO, HNCACB, and HNCOCACB) on a Varian 600 MHz 
spectrometer with additional verification from a 15N-dispersed NOESY on a Bruker Avance 
800MHz spectrometer. All assignment experiments were performed using cryogenic probes 
at 500 μM protein. Assignments were obtained for 88 of 94 residues in Dcp2 1–94 (the 
regulatory domain) and for 104 of 148 residues in Dcp2 95–243 (the catalytic domain). In 
Dcp2 95–243 the majority (30 of 44) of the unassigned residues were in a loop (from 194–
224) that is not visible in the nitrogen HSQC.
Small-angle X-ray scattering
Samples were purified as described and subjected to gel filtration chromotography using a 
Superdex G75 column in 150 mM NaCl, 2 mM DTT and 50 mM HEPES pH 7.0. All SAXS 
experiments were done on stoichiometric Dcp1-Dcp2 complex with mutations in Dcp2 as 
indicated. Raw data was processed via scripts provided by ALS Beamline 12.3.1 scientists49 
and buffer was subtracted. In some cases buffer subtraction was done manually by 
reweighting the normalization of the protein scattering to the buffer scattering because there 
were small differences in nucleotide concentration between protein and buffer blank. This 
manual subtraction did not affect the distance distribution function and was used to achieve 
an intensity curve that asymptotes to zero at high values of momentum transfer. In no case 
was this correction larger than 5%. Following raw data processing, distance distribution 
functions were computed using GNOM50. Dmax was explored between 80 and 150 Å in 
increments of 5 Å and the smallest value that led to a monotonic decrease towards 
P(Dmax)=0 was selected. P(Dmax)=0 was then enforced via GNOM. Notably the Dmax 
parameter is simply an integration limit for the indirect Fourier transform method of 
calculating the distance distribution function and is not necessarily a measure of the 
maximum particle dimension since it is highly sensitive to aggregation50–52.
Decapping assays
Proteins were purified as described and subjected to gel filtration chromatography using a 
Superdex G75 column in buffer containing 100 mM NaCl, 5% (v/v) glycerol, 5 mM DTT 
and 50 mM HEPES pH 7.5. Proteins were prepared for kinetics asdescribed35. Rates were 
measured at a series of enzyme concentrations on a 29-mer substrate27 in an iceblock at ~0.1 
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°C. Rates for each enzyme concentration were calculated by dividing the initial rate during 
the linear phase of the reaction by the endpoint of 0.85. Each assay was repeated at least 
twice and the rate for each enzyme concentration averaged between experiments. These 
average rates were then plotted versus concentration with error bars representing the 
standard error of the mean between independent experiments. Data were fitted to extract KM 
and kmax as described35.
Solvent accessibility calculations
The solvent-accessible surface area53 (SASA) for the regulatory domain was calculated 
using the program area imol within the CCP4 suite54. The open and closed SASA values 
were calculated using the open or closed crystal structures, respectively (PDB entry 2QKM, 
ref. 26). The SASA for each residue was normalized to 75% of the maximum value 
calculated from a Gly-X-Gly tripeptide55. The factor of 75% was introduced because the 
helical 31–52 region is less exposed than a Gly-X-Gly tripeptide and the largest observed 
SASA was close to 75% of the Gly-X-Gly value (residue 33).
Multiple sequence alignments
Sequences for Dcp2 from ten organisms were retrieved from the NCBI database, aligned 
using MUSCLE56, and visualized using Jalview57. Shown in Figure 1 is a fragment of an 
alignment that was carried out using default MUSCLE parameters on the entire sequence of 
Dcp2. The species used for the alignment were S. pombe, S. cerevisiae, C. albicans, A. 
thaliana, C. elegans, D. melanogaster, X. laevis, D. rerio, M. musculus and H. sapiens, with 
8 of these shown.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Mutants along the interdomain interface in the closed crystal form attenuate the catalytic 
step of decapping. (a) Dcp2 consists of an N-terminal regulatory domain (1–94, purple), a 
catalytic domain of the Nudix superfamily (95–243, green with the Nudix motif in red), and 
a large, nonconserved C-terminal region of unknown function (244–741, brown). A 
sequence alignment is provided of residues 30–50 of Dcp2 with absolutely conserved 
residues highlighted in yellow. For residues 30–50 the solvent accessible surface area 
(SASA) is shown on a relative scale from buried to exposed in both the open (o) and closed 
(c) crystal forms, for details see Methods. (b) The interface between the regulatory domain 
(purple) and the catalytic domain (green) in the closed, ATP-bound crystal structure is 
shown with sites of mutation highlighted (PDB entry 2QKM, ref. 26). Dcp1 is in gold and 
the catalytic Nudix helix of Dcp2 is in red. (c) Observed rate constants for decapping assays 
of various constructs as marked. Solid lines are fit to a rate equation appropriate for single-
turnover kinetics, where enzyme is in excess of substrate (see Supplementary Note)35. Error 
bars are standard error in the mean for the rate measured in two or more independent 
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experiments. (d) The rate of the catalytic step (kmax) is plotted on a log scale for selected 
interface mutants; error is s.e.m.
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Figure 2. 
Some interface mutants block conversion to the closed form measured by SAXS. (a) 
Experimental SAXS curves for the wild-type Dcp1-Dcp2 complex (D1D2) and mutants. 
Shown is the momentum transfer s, where 2θ is the scattering angle and λ is the X-ray 
wavelength. Scattering curves are artificially displaced along the ordinate for clarity. (b) 
Plotted is the distance distribution function P(r) vs interatomic separation (r) for the wild-
type decapping complex. Unliganded Dcp1-Dcp2 complex (D1D2) is in black and the curve 
in the presence of 10 mM m7GpppA is in red. A compaction is evident by the reduced 
probability between 60 Å and 100 Å in nucleotide bound (red) versus apo (black). (c) The 
observed compaction is blocked upon W43A mutation of Dcp2. (d) The R167Q mutation of 
Dcp2 still closes upon addition of nucleotide.
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Figure 3. 
The regulatory domain has a specific binding site for m7G. (a) The regulatory domain 
colored by chemical shift perturbation upon addition of 30 mM m7GDP. Sites of mutation 
and quantitative analysis Trp43 and Asp47 are indicated. (b) A view of the Dcp1-Dcp2 
complex aligned with the isolated regulatory domain (PDB entry 2QKM, ref. 26). Colors as 
in figure 1b. (c,d) HSQC spectral overlay of the Trp43 indole region (c) or the Asp47 
backbone (d) while being titrated by m7GDP. Concentrations of nucleotide shown are 0mM 
(red), 2.5 mM (orange), 5 mM (green), 10 mM (cyan), 20 mM (pink), and 30 mM (purple). 
(e,f) HSQC spectral overlay of the Trp43 indole region (e) or the Asp47 backbone (f) over 
the same concentration range of GDP.
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Figure 4. 
The catalytic domain binds m7GDP on the catalytic helix and binds a variety of nucleotides 
along the RNA binding region. (a) The catalytic domain colored by chemical shift 
perturbation upon addition of 30 mM m7GDP. Amide groups of Glu146 and Lys235 are 
used as representatives for binding to the catalytic helix and the RNA binding region, 
respectively. Blue indicates resonances that were broadened beyond detection upon addition 
of nucleotide. (b) The catalytic domain colored by chemical shift perturbation upon addition 
of 30 mM ATP on the same scale as (a). (c) A view of the Dcp1-Dcp2 complex aligned with 
the isolated catalytic domain (PDB entry 2QKM, ref. 26). Colors as in Figure 1b, with the 
RNA-binding region highlighted in blue. (d, e) HSQC spectral overlay of Lys235 (d) or 
Glu146 (e) while being titrated by m7GDP. Colors are the same as in Figure 3. The noise in 
the m7GDP Glu146 region results from incomplete suppression of uncoupled magnetization 
of nucleotide due to the phase cycling used in the FHSQC sequence and did not affect 
interpretation of the data or the fit.46 (f, g) HSQC spectral overlay of Lys235 (f) or Glu146 
(g) being titrated with ATP.
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Figure 5. 
Decapping by Dcp2 proceeds by formation of a composite active site involving both the 
regulatory and catalytic domains. (a) Regions on the regulatory and catalytic domains that 
are perturbed by m7GDP or m7GpppA cap analog but not other nucleotides are indicated 
with a bar. Residue boundaries of the regions are indicated above the diagram. Conserved 
residues are shown in capital letters and those that have strong effects on decapping in vivo 
when mutated are marked with a *. Highlighted in red is the conserved Nudix motif, 
consisting of GX5EX7REUXEEXGU with X any residue and U is I, L, or V. (b) 
Isomerization into the active form requires direct interactions of both domains with cap. 
Colors as in Figure 1b with RNA indicated in blue with a hexagon cap. (c) Once the active 
state is formed decapping proceeds efficiently using a composite active site with cap 
sandwiched between the two domains.
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Table 1
Kinetic rate constants for Dcp2 in vitro.
Protein KM (μM)1 kmax (min−1)1 kmax/KM (min−1/μM) kmax/KM (mut/WT)
WT Dcp2 1–243 10.1 ± 2.30 9.98×10−2 ± 1.16×10−2 9.88×10−3 1
W43A 7.42 ± 0.938 6.52×10−3 ± 3.00×10−4 8.78×10−4 0.089
D47A 5.43 ± 0.737 1.19×10−3 ± 5.20×10−5 2.19×10−4 0.022
R167Q 16.2 ± 4.75 1.18×10−1 ± 1.41×10−2 7.28×10−3 0.74
Dcp2 1–243 + Dcp1 4.33 ± 0.487 6.19×10−1 ± 3.01×10−2 1.43×10−1 14
1
Error is s.e.m.
Nat Struct Mol Biol. Author manuscript; available in PMC 2011 March 01.
